Kevin Patrick Danahy - 17 Mar 2022 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)

Role: Chief Executive Officer
Signature: /s/ Kenneth B. Stratton, as Attorney-in-Fact
Issuer symbol: PLSE
Transactions as of: 17 Mar 2022
Net transactions value: $0
Form type: 4
Filing time: 24 Mar 2023, 16:31:25 UTC
Previous filing: 22 Mar 2022
Next filing: 27 Sep 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PLSE	Stock Option (right to buy)	Award	$0	+25,000		$0.000000	25,000	17 Mar 2023	Common Stock	25,000	$6.41	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On February 14, 2022, the reporting person was granted an option to purchase 150,000 shares of the Issuer's common stock. The option vests upon the achievement of performance objectives, with vesting targets of 25% vesting per year upon achievement of said objectives established by the Issuer's Compensation Committee, subject to the reporting person's continued service through each vesting date. The performance objectives for 2022 were met, resulting in the vesting of the option as to 25,000 shares.

Content

On February 14, 2022, the reporting person was granted an option to purchase 150,000 shares of the Issuer's common stock. The option vests upon the achievement of performance objectives, with vesting targets of 25% vesting per year upon achievement of said objectives established by the Issuer's Compensation Committee, subject to the reporting person's continued service through each vesting date. The performance objectives for 2022 were met, resulting in the vesting of the option as to 25,000 shares.